Saturday, March 23, 2019 9:57:47 PM
I am postulating if the drop is related to the absence of synergistic effect on MSSA. Of course the trial design at this scale was not for proving efficacy, but it did show some light on the potential effect of CF-301.
Second, the MRSA proportion in Phase II is about 35-40%, it is suspicious if this composition can be sustained in Phase III, although management said this range of MRSA is expected. Since CF-301 is highly effective in MRSA but not in MSSA when used with SoC. The composition of the study population greatly affects the overall efficacy. In other words, if Phase III does not have MRSA portion like this time, then likely we are seeing reduced overall efficacy.
For the left-sided endocarditis, I think it doesn't impose much pressure on stock price. I think from the very beginning, there is limited hope on left-sided endocarditis since it is really difficult to treat with medication. Daptomycin was also approved for bacteremia and right-sided endocarditis around 13 years ago.
However, overall speaking, I think CF-301 likely to show effect on MRSA cases and maybe some effect on MSSA (if left-sided endocarditis is excluded, likely we may see somer effect in Phase III). Therefore, I still think CFRX is a good risk/reward candidate at this share price.
Recent CFRX News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:24:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 09:41:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 09:30:55 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/03/2023 09:08:09 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/03/2023 04:16:01 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/30/2023 09:24:34 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/24/2023 08:06:07 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/23/2023 08:05:56 PM
- ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study • GlobeNewswire Inc. • 10/16/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/29/2023 03:15:52 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/25/2023 12:00:18 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM